Abonnement à la biblothèque: Guest
Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections
International Journal of Medicinal Mushrooms
Facteur d'impact: 1.423 Facteur d'impact sur 5 ans: 1.525 SJR: 0.431 SNIP: 0.661 CiteScore™: 1.38

ISSN Imprimer: 1521-9437
ISSN En ligne: 1940-4344

Volume 21, 2019 Volume 20, 2018 Volume 19, 2017 Volume 18, 2016 Volume 17, 2015 Volume 16, 2014 Volume 15, 2013 Volume 14, 2012 Volume 13, 2011 Volume 12, 2010 Volume 11, 2009 Volume 10, 2008 Volume 9, 2007 Volume 8, 2006 Volume 7, 2005 Volume 6, 2004 Volume 5, 2003 Volume 4, 2002 Volume 3, 2001 Volume 2, 2000 Volume 1, 1999

International Journal of Medicinal Mushrooms

DOI: 10.1615/IntJMedMushrooms.2019030320
pages 401-411

Thirteen-Week Oral Toxicity Evaluation of Erinacine AEnriched Lion's Mane Medicinal Mushroom, Hericium erinaceus (Agaricomycetes), Mycelia in Sprague-Dawley Rats

Li-Ya Lee
College of Veterinary Medicine, National Chung Hsing University, Taichung City, Taiwan
I-Chen Li
Bioengineering Center, Grape King Bio Ltd, Taoyuan City, Taiwan
Wan-Ping Chen
Testing Center, Super Laboratory Inc., New Taipei City, Taiwan
Yueh-Ting Tsai
Department of Food Science, Nutrition and Nutraceutical Biotechnology, Shih Chien University, Taipei City, Taiwan
Chin-Chu Chen
Bioengineering Center, Grape King Bio Ltd, Taoyuan City, Taiwan; Department of Food Science, Nutrition and Nutraceutical Biotechnology, Shih Chien University, Taipei City, Taiwan; Institute of Biotechnology, National Changhua University of Education, Changhua County, Taiwan
Kwong-Chung Tung
College of Veterinary Medicine, National Chung Hsing University, Taichung City, Taiwan


Recently, erinacine A-enriched Hericium erinaceus (EAHE) mycelia have demonstrated therapeutic efficacy in animal models of neurodegenerative disease, including Alzheimer and Parkinson disease. Despite promising results from animal models, there have been no reports on its toxicity after long-term consumption. Hence, the present study was designed to evaluate the safety of EAHE mycelia through a 13-week subchronic rodent feeding study. Following 13 weeks of EAHE mycelia feeding at dosages of 0, 875, 1750, and 2625 mg/kg body weight in both male and female Sprague-Dawley rats, findings revealed neither any mortalities nor noticeable toxicological effects in all the rats during the investigation period. Physiological parameters including body weight and feed consumption patterns were unaffected by EAHE mycelia administration. The hematological and biochemical parameters as well as histopathological studies revealed no significant differences between the treatment and control groups. Conclusively, the obtained results suggested that EAHE mycelia could be relatively unharmful when used over an extended period, supporting its safe use in food preparation.


  1. Mizuno T. , Bioactive substances in Hericium erinaceus (Bull.: Fr.) Pers. (Yamabushitake), and its medicinal utilization. Int J Med Mushrooms. 1999;1(2):105–19.

  2. Friedman M. , Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (lion’s mane) mushroom fruiting bodies and mycelia and their bioactive compounds. J Agric Food Chem. 2015;63(32):7108–23.

  3. Shimbo M, Kawagishi H, Yokogoshi H. , Erinacine A increases catecholamine and nerve growth factor content in the central nervous system of rats. Nutr Res. 2005;25(6):617–23.

  4. Kawagish H, Zhuang C. , Compounds for dementia from Hericium erinaceum. Drugs Future. 2008;33(2):149–55.

  5. Obara Y, Nakahata N. , The signaling pathway of neurotrophic factor biosynthesis. Drug News Perspect. 2002;15(5):290–8.

  6. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. , Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytother Res. 2009;23(3):367–72.

  7. Ma BJ, Shen JW, Yu HY, Ruan Y, Wu TT, Zhao X. , Hericenones and erinacines: stimulators of nerve growth factor (NGF) biosynthesis in Hericium erinaceus. Mycology. 2010;1(2):92–8.

  8. Mori K, Obara Y, Hirota M, Azumi Y, Kinugasa S, Inatomi S, Nakahata N. , Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells. Biol Pharm Bull. 2008;31(9):1727–32.

  9. Kawagishi H, Shimada A, Shirai R, Okamoto K, Ojima F, Sakamoto H, Ishiguro Y, Furukawa S. , Erinacines a, b and c, strong stimulators of nerve growth factor (NGF)-synthesis, from the mycelia of Hericium erinaceum. Tetrahedr Lett. 1994;35(10):1569–72.

  10. Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, Furukawa Y, Hayashi K, Nabeshima T. , Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer’s disease. Behav Brain Res. 1997;83(1-2):117–22.

  11. Lee KF, Chen JH, Teng CC, Shen CH, Hsieh MC, Lu CC, Lee KC, Lee LY, Chen WP, Chen CC, Huang WS, Kuo HC, Protective effects of Hericium erinaceus mycelium and its isolated erinacine A against ischemia-injury-induced neuronal cell death via the inhibition of iNOS/p38 MAPK and nitrotyrosine. Int J Mol Sci. 2014;15(9):15073–89.

  12. Kuo HC, Lu CC, Shen CH, Tung SY, Hsieh MC, Lee KC, Lee LY, Chen CC, Teng CC, Huang WS, Chen TC, Lee KF, Hericium erinaceus mycelium and its isolated erinacine A protection from MPTP-induced neurotoxicity through the ER stress, triggering an apoptosis cascade. J Transl Med. 2016;14:78.

  13. Tzeng TT, Chen CC, Lee LY, Chen WP, Lu CK, Shen CC, Huang F. CY, Chen CC, Shiao YJ. , Erinacine A-enriched Hericium erinaceus mycelium ameliorates Alzheimer’s disease-related pathologies in APPswe/PS1dE9 transgenic mice. J Biomed Sci. 2016;23(1):49.

  14. Li IC, Chen YL, Lee LY, Chen WP, Tsai YT, Chen CC, Chen CS. , Evaluation of the toxicological safety of erinacine A-enriched Hericium erinaceus in a 28-day oral feeding study in Sprague-Dawley rats. Food Chem Toxicol. 2014;70:61–7.

  15. Li IC, Chen YL, Chen WP, Lee LY, Tsai YT, Chen CC, Chen CS. , Genotoxicity profile of erinacine A-enriched Hericium erinaceus mycelium. Toxicol Rep. 2014;1:1195–201.

  16. National Research Council. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press; 2011.

  17. Organization for Economic Co-operation and Development. Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents. 1998. Available from: http://dx.doi.org/10.1787/9789264070707-en.

  18. FDA. Part 58—Good laboratory practice for nonclinical laboratory studies. 2011. Available from: https://www.accessdata. fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=58&showFR=1&subpartNode=21:

  19. Piao Y, Liu Y, Xie X. , Change trends of organ weight background data in Sprague Dawley rats at different ages. J Toxicol Pathol. 2013;26(1):29–34.

  20. Cummings JL, Morstorf T, Zhong K. , Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther. 2014;6(4):37.

  21. Lakshmanan H, Raman J, David P, Wong KH, Naidu M, Sabaratnam V. , Haematological, biochemical and histopathological aspects of Hericium erinaceus ingestion in a rodent model: A sub-chronic toxicological assessment. J Ethnopharmacol. 2016;194:1051–9.

  22. Martel J, Ojcius DM, Chang CJ, Lin CS, Lu CC, Ko YF, Tseng SF, Lai HC, Young JD. , Anti-obesogenic and antidiabetic effects of plants and mushrooms. Nat Rev Endocrinol. 2017;13(3):149–60.

  23. Mukinda JT, Eagles PFK. , Acute and sub-chronic oral toxicity profiles of the aqueous extract of Polygala fruticosa in female mice and rats. J Ethnopharmacol. 2010;128(1):236–40.

  24. Levine B. , Animal clinical pathology. In: Derelanko MJ, editor. Handbook of toxicology. 2nd ed. CRC Press (FL): Informa Healthcare; 2001.

  25. Giknis M, Clifford C. , Clinical laboratory parameters for Crl: CD(SD) rats. Wilmington (MA): Charles River Laboratories; 2006.

  26. Lum G. , Significance of low serum alkaline phosphatase activity in a predominantly adult male population. Clin Chem. 1995;41(4):515–8.

Articles with similar content:

Antioxidant Action of an Aqueous Extract of Royal Sun Medicinal Mushroom, Agaricus brasiliensis (Agaricomycetes), in Rats with Adjuvant-Induced Arthritis
International Journal of Medicinal Mushrooms, Vol.20, 2018, issue 2
Adelar Bracht, Geferson de Almeida Gonсalves, Anacharis B. de Sá-Nakanishi, Maria Raquel Marсal Natali, Rosane Marina Peralta, Andréia Assunсão Soares, Aline Cristine da Silva de Souza, Ana Paula de Santi-Rampazzo
Effects of Concurrently Administered Aqueous Extract of Lingzhi or Reishi Medicinal Mushroom, Ganoderma lucidum (Agaricomycetes), and Lead Acetate in Rats
International Journal of Medicinal Mushrooms, Vol.21, 2019, issue 2
Michael T. Sobowale, Raymond I. Ozolua, Buniyamin A. Ayinde, Dickson O. Uwaya
Antioxidant Effects of Medicinal Mushrooms Agaricus brasiliensis and Ganoderma lucidum (Higher Basidiomycetes): Evidence from Animal Studies
International Journal of Medicinal Mushrooms, Vol.17, 2015, issue 10
Solomon P. Wasser, Nataliya O. Sybirna, Borys Yurkiv, Eviatar D. Nevo
Developmental Toxicity Assessment of Medicinal Mushroom Antrodia cinnamomea T.T. Chang et W.N. Chou (Higher Basidiomycetes) Submerged Culture Mycelium in Rats
International Journal of Medicinal Mushrooms, Vol.13, 2011, issue 6
Tai-I Chen, Ting-Wei Lin, Di-Sheng Wang, Chin-Chu Chen, Chiao-Wen Chen
Effects of Diets Supplemented with Medicinal Mushroom Myceliated Grains on Some Production, Health, and Oxidation Traits of Dairy Ewes
International Journal of Medicinal Mushrooms, Vol.21, 2019, issue 1
Antonino Di Grigoli, Giuseppe Di Miceli, Maria Letizia Gargano, Felicia N. Anike, Marco Alabiso, Francesca Vitale, Giuseppe Venturella, Omoanghe S. Isikhuemhen, Massimo Todaro, Adriana Bonanno